Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jul 17, 2023
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different types of nicotine affect the body and mind of experienced e-cigarette users. Participants will use three forms of nicotine: one from natural tobacco, one that is synthetic (man-made), and a mix of both. The researchers want to understand how the body processes these types of nicotine, how they impact heart health, and how they influence cravings or enjoyment when vaping.
To join this study, participants should be healthy and regularly use e-cigarettes—at least 15 days in the last month. However, some people may not be eligible, such as those taking certain medications, pregnant or breastfeeding women, or anyone who has allergies to specific substances used in vaping. If you decide to participate, you can expect to vape in a controlled setting while the team monitors your reactions and collects information about your experiences. This trial is currently recruiting participants aged 18 to 70, regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy on the basis of medical history and limited physical examination.
- • Current regular user of E-Cigarettes (≥ 15 days in the past 30 days)
- Exclusion Criteria:
- • • Medications
- • Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs).
- • Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers).
- • Concurrent use of nicotine-containing medications (Example: nicotine patch, lozenge, gum).
- • Any stimulant medications (example: Adderall) generally given for ADHD treatment.
- • • Pregnancy
- • Pregnancy (self-reported and urine pregnancy test)
- • Breastfeeding (determined by self-report)
- • Women of childbearing potential must be using an acceptable method of contraception
- • Inability to read and write in English
- • A known propylene glycol/vegetable glycerin allergy
- • Uncomfortable with getting blood drawn
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Neal Benowitz, MD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported